Posts in tag

electrophysiology


Catheter-based ablation is a common procedure for treating cardiac arrhythmias but carries a risk of collateral damage to healthy surrounding tissue. Pulsed-field ablation (PFA) is emerging as the newest treatment modality for catheter ablation, offering improvements in both procedure speed and safety. Though the technology is still largely in development, it has caught the attention …

Westport, CT, May 28, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc. would …

Westport, CT, April 08, 2021 (GLOBE NEWSWIRE) — Leading industry publication highlights the rising importance of intracardiac signals in complex cardiac ablations that treat irregular heart rhythm disorders High-quality intracardiac signals are deemed essential to determine ablation endpoints PURE EP™’s signals are described as ‘indispensable’ by the physician user BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” …

Electrophysiology Devices – Breaking Through the Bottlenecks of Effective Arrhythmia Treatment Successful patient outcomes are taking over products and services as the key focal point of the healthcare industry. This reorientation of focus toward patient satisfaction and outcomes in healthcare pools is reinforcing the adoption of technology. For healthcare providers, technology has not only emerged …

Westport, CT, June 04, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that two scientific sessions highlighting PURE EP(tm) System have been …

Westport, CT, Sept. 05, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that its subsidiary, NeuroClear Technologies, Inc., raised $3.7 million in an initial seed round. Founded in November 2018, NeuroClear …